As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion’s scientific and drug development expertise to support drug development programs of Celerion’s clients. He is a member of Celerion’s respiratory and vaccine research teams and is the scientific liaison to various external experts in the fields of pulmonology and vaccine development.
Anna Sipitanou is the Business Development Manager for Copley Scientific. She holds a BSc in Chemistry and an MSc in Drug Discovery & Pharmaceutical Sciences. Having joined Copley Scientific in 2017, Anna plays a key role in the company’s technical and sales support services, including the training of customers on a wide range of pharmaceutical testing equipment, with a particular focus on OINPD testing.
Manager Aerosol Research and Dosimetry at Philip Morris International Research and Development
Arkadiusz K. Kuczaj earned his PhD (2006) in the field of Applied Mathematics from the University of Twente, the Netherlands. As Manager of Aerosol Research and Dosimetry, he is currently leading aerosol delivery and characterization, in vitro exposure, and in vivo inhalation research in the Biomedical Research Department (BMRD) at Philip Morris International R&D (PMI R&D) in Neuchatel, Switzerland.
He published and co-authored more than 30 technical manuscripts in the field of life-science, aerosol research, computational physics and fluid dynamics.
Beatriz Noriega Fernandes holds a MSc Degree in Biological Engineering by Instituto Superior Técnico, University of Lisbon, 2015.
She joined Hovione in the same year as an Industrial PhD Candidate in collaboration with Faculty of Pharmacy, University of Lisbon, specializing in dissolution methodologies and in vivo/in vitro correlations for dry powder inhaler formulations.
Bernhard Müllinger is Chief Operating Officer General Manager at Resyca. With the resyca team he provides seamless outsourcing services for drug-device combination products in liquid formulations. He has worked on smart nebuliser devices and has extensive experience in medical device development and clinical development of combination products. Before joining Resyca Bernhard has worked at Vectura, Activaero, Inamed-CRO, at the Asklepios Clinic and at the Helmholtz-Zentrum.
David is a physical chemist (holding a PhD in Surface Chemistry and Colloid Science) with extensive medicine development experience. He spent 32 years with GlaxoSmithKline, in a range of increasingly senior scientific and management positions both in Research and Development and in Manufacturing. During that time, he and his teams assisted in the development of 5 respiratory medicines from molecule selection to be amongst today's gold standard treatments for asthma and chronic obstructive pulmonary disease.
Felix is a pharmacist by training with a PhD in pharmacology. In 2006, he joined Boehringer Ingelheim as a trainee, focusing on launch and transfer activities of inhalative products. He then took over different roles at BI microParts in Dortmund at the development site of inhalation devices as development QA manager, senior project manager, and lab head of device development.
Business Development professional with a background in Pharmaceutical Sciences. Over 12 years of experience acquired in Business Development (pipeline and portfolio management), Quality and Operations, and R&D, in Pharma Industry and Academia. Most relevant experience includes building an internal pipeline of 505b2 and generic products in Ophthalmology, Dermatology and Respiratory fields.
Jeffry Weers is currently the Chief Technical Officer at Respira Therapeutics, Inc. He holds a B.S. degree in Chemistry from the University of Puget Sound (1980), and a Ph.D. in Physical Chemistry from the University of California, Davis (1985).
Previously, Jeff was the Chief Scientific Officer for Respiratory at Novartis Pharmaceuticals Corporation (2009-2017). Prior to joining Novartis, Jeff spent roughly a decade (1999-2008) with Nektar Therapeutics (formerly Inhale Therapeutic Systems), where he held various positions within the Research and Development organization.
Dr Jörg Schiewe is the Head of Global CMC Experts at Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
He studied chemistry at the Martin-Luther-University in Halle, Germany and earned his PhD in the field of physical chemistry in 1994. The Alexander von Humboldt foundation awarded Dr. Schiewe a Feodor-Lynen-Fellowship to perform post-doctoral work with Prof. Alan Bond at Monash University in Melbourne, Australia (1995-1997).
Marco Laackmann has an Engineering degree in Chemical Engineering applied Biotechnology from University of Applied Science Emden in Germany and a MBA from Bradford School of Management in UK.
His background includes 15 years of experience in various areas of Dry Powder Inhaler covering aspects of device development, manufacturing and quality control of medical devices as well as powder dosing technologies and process development.
Mark has worked with Swellaway Ltd. for >3yrs. in a NED role with a special focus on Digital Health Regulatory, IP and commercialisation. Mark holds a full-time role for more than 13yrs with TEVA Pharmaceuticals and over 16years with AstraZeneca prior to this. Mark has held various positions including R&D Project Leader, VP Sales & Marketing, Strategic Planning & Business Development, and Global Brand Lead. Graduated in Aeronautical Sciences and completed his MBA at Durham University, UK.
Since 1994 working in the Pharma Industrie 7 years at Robert Bosch GmbH as head of product management and technical director for capsule, blister, antibiotica,- filling machines. founding 2001 at mematec consulting, here mainly worked for Companies as Harro Hoefliger to design capsule filling equipment and filling equipment for inhalers, Rohwedder GmbH to design assembly machines for medical and Pharma application.
Martin Wing-King is the Director of Project Management at Quotient Sciences’ Reading, UK facility. Martin began his career in Analytical Development at Johnson Matthey, and over the course of 8 ½ years transitioned from the lab into a sales role within the company.
Senior Director of Pharmaceutical Development and Technical Operations at Acorda Therapeutics
Michael Tauber is Senior Director of Pharmaceutical Development and Technical Operations at Acorda Therapeutics. Since 2002, he has worked in various areas of pharmaceutical development including early and late stage development, pre-formulation and formulation for solid oral development, formulation and scale up of spray dried engineered particles for inhalation delivery and management of CMC related activities supporting the development and commercialization of Inbrija®.
Nélio Drumond is a PharmD by training with a PhD in Patient Centric Drug Product Design. He shares several years of experience in the Pharmaceutical Industry providing scientific leadership to govern the formulation and manufacturing aspects of drug product development projects during clinical stages, including their subsequent scalability and validation for commercial use.
Dr. Roldan works as lead scientist and project manager at AlveoliX since 2019. Currently, she is responsible for the development and implementation of microphysiological system/organ-on-chip approaches for early- and late-phase drug development. Her research involves generating human models of the distal airways that can be used for safety and efficacy testing, as well as for inhalation toxicology.
Paul Johnson is an independant consultant specialising in the pharmaceutical development of inhalation drug delivery systems. He has provided consultancy services to both NCE and generic drug development companies since 2018. Prior to this Paul gained 20 years of experience in leading the CMC aspects of much of GSK's respiratory portfolio, including leading Relvar Ellipta from early research to registration, launch and lifecycle management.
Peter Robbins is Professor of Physiology at the University of Oxford. He has a strong reputation for developing innovative technologies to address previously intractable questions in human physiology, particularly relating to respiratory and cardiovascular function. His interests include hypoxia biology and iron homeostasis. In these areas, he has had a long-term collaboration with Professor Sir Peter Ratcliffe, the 2019 Nobel Laureate in Physiology or Medicine.
Professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria
Prof. Dr. Sven Stegemann is professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria. Over the course of his 27-year career in the pharmaceutical industry, he has worked as an advisor to major pharmaceutical companies on ways to improve the design, development and manufacture of pharmaceutical products so they better address the individual needs of patients.
Thomas is a research scientist in the field of mucosal immunology and therapeutics. He is particularly concerned about infectious diseases and the way we can prevent them. Quickly realized the importance of the host-pathogen-environment triad in determining the outcome of infectious events and he was fascinated by the host-pathogen dualism and how their interactions dictate pathogenesis and subsequently modulate the efficacy of therapeutics. Studying this in more details has always been the driving force of my research.
Tonya Winders. MBA is currently the President and Chief Executive Officer of Allergy & Asthma Network, the leading patient advocacy organization dedicated to ending the needless death and suffering due to asthma, allergies and related conditions.
Tonya has over 17 years experience in leadership roles within the allergy and asthma industry. From sales and marketing leadership to managed markets access, she has worked tirelessly to ensure patients have access to effective diagnostic and treatment tools.